SUMMARY The interaction of acetylcholine receptor antibodies with different kinds of human skeletal muscle receptor was investigated. The reaction of most receptor antibodies was strongest with receptor from a patient with myasthenia gravis and with receptor from denervated muscle. Results obtained with these receptors were well correlated. The binding of most receptor antibodies to receptor from functionally normal muscle was much weaker and also qualitatively different. In a few patients with moderate and severe clinical symptoms the existence of acetylcholine receptor antibodies was revealed only by their reaction with receptor from myasthenic muscle. One patient had a clone of receptor antibodies reacting exclusively with receptor from her own muscle.
The analysis of acetylcholine receptor antibodies has become a valuable tool in the diagnosis of myasthenia gravis and in the monitoring of treatment of this disease. In the individual patient changes in the intensity of the myasthenic symptoms usually coincide with changes in the receptor antibody concentration, but there is no close covariance between the concentration of receptor antibodies and the clinical stage and the disease intensity in a myasthenia gravis population. ' The most frequent analytical methods in routine use are based on Separation of acetylcholine receptor and acetylcholine receptor-IgG complexes from myasthenic muscle The cholinergic receptor and receptor-IgG complexes were extracted from homogenated muscle as described.' The free receptor was separated from receptor complexed with IgG by gel filtration on Sephacryl G 300 Superfine (Pharmacia Fine Chemicals, Sweden) at room temperature. The column (5 x 100 cm) was equilibrated in phosphate buffer, 0 05 mol/l with NaCI, 01 mol/l and EDTA, 0-001 mol/l, pH 7-4, with Triton X-100 0-5 % and Trasylol to 106
Kallikrein inhibitory units/I. Fractions of 5 ml were collected at a rate of 15 ml/h. The content of IgG in the fractions was measured using an immunoassay.'
The sensitivity of this assay is in the order of 0-5 mg/I. The toxin binding capacity of the fractions was measured as described.' The receptor-IgG complex was found in the void volume (fractions n:o 99-108) whereas the uncomplexed receptor was mainly found in fractions 115-131. The uncomplexed receptor extract was further concentrated and separated by gel filtration using a column (25 x 40 cm) of Sephadex G25 equilibrated in the same buffer.
Preparation of '251-labelled o-neurotoxin from the venom of Naja naja siamensis, our routine assay for receptor antibodies directed against sites other than the toxin binding site and the assay for receptor antibodies interfering 1i'ith the toxin binding site were performed as described earlier.' 6 The cholinergic receptor preparations from the normal and from the denervated muscle were diluted to the same concentration (measured as toyin binding capacity) as that of the receptor from the myasthenic muscle. In all assays, the same amount of the three receptors were used (0 1 pmol toxin binding sites/assay). The results of the assay of antibodies interfering with the toxin binding site were expressed in % inhibition of toxin binding using the effect of normal IgG as zero. The results of the assay for antibodies against sites other than the toxin binding site were expressed in arbitrary units/I, as the amount of receptor antibody in the sample compared with the amount of normal IgG.1 Using normal sera in this assay, the amount of CPM precipitated with normal muscle receptor was 150-202, with denervated muscle receptor 173-188, and with myasthenic muscle receptor 161-203. These low background values also in the case of the myasthenic muscle receptor preparation also is a proof that all receptor-IgG complexes had indeed been removed from the preparation. 
Results
The reactions of receptor antibodies from different patients with different receptor preparations were tested by using the three antigen preparations in the two kinds of analysis for receptor antibodies. In a preliminary study no significant differences were found using denervated muscle receptor from different patients nor using normal muscle receptor from different patients.
Sera from 59 patients were tested with the assay for receptor antibodies directed against sites other than the toxin binding site using the three different antigen preparations. Ten sera were from patients with moderate or severe symptoms and a repeatedly negative routine analysis earlier. The results obtained with the other 49 sera are shown in Fig. 1 . Antigen from the myasthenic muscle reacted much better with almost all sera tested than antigen from denervated muscle, while antigen from the normal muscle showed the weakest reaction. There were significant differences between the values obtained with myasthenic muscle and denervated muscle (level of significance 0 005), between myasthenic muscle and normal muscle (level of significance 0-001) as well as between denervated and normal muscle (level of significance 0 01). Linear correlation coefficients between results obtained with myasthenic and denervated receptor was 0-83, between myasthenic and normal receptor 0 30 and between denervated and normal receptor 0-20.
Ten sera which in repeat routine examinations been regarded as negative reacted exclusively with the antigen from the myasthenic muscle. The Inhibition of toxin binding to receptor was studied using the different receptor preparations. Serum from the myasthenic patient inhibited maximally 600% of the toxin binding to receptor from her own muscle, and 40 and 60%, respectively, of the binding to denervated and normal muscle receptor. The fraction of this receptor antibody with pl 8 88-9-93 inhibited maximally 25 % of toxin binding to the myasthenic muscle only. Sera from 12 other patients were tested on their ability to inhibit toxin binding to the different antigen preparations. All these sera had high concentrations of antibodies reacting with sites other than the toxin binding site. Also in this modification of assay the receptor prepared from the myasthenic muscle showed the best reaction with the majority of the sera (Fig. 3) . The 
